ArticleNanoscale2015
Self-carried curcumin nanoparticles for in vitro and in vivo cancer therapy with real-time monitoring of drug release.
Article in Nanoscale, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Thermally activated delayed fluorescence materials: innovative design and advanced application in biomedicine, catalysis and electronics.RSC advances · 2025Review
- Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy.Pharmaceutics · 2025Review
- Targeted co-delivery nanosystem based on methotrexate, curcumin, and PAMAM dendrimer for improvement of the therapeutic efficacy in cervical cancer.Scientific reports · 2025Article
- Drug self-delivery systems: A comprehensive review on small molecule nanodrugs.BioImpacts : BI · 2025Review
- Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives.International journal of nanomedicine · 2025Review
- Nanotechnology Advances Proteolysis Targeting Chimeras (PROTACs): Transition From Basic Research to Clinical Application.International journal of nanomedicine · 2025Review
- From Bench to Bedside: ROS-Responsive Nanocarriers in Cancer Therapy.AAPS PharmSciTech · 2024Review
- Instantly adhesive and ultra-elastic patches for dynamic organ and wound repair.Nature communications · 2024Article
- Enhanced Dissolution and Bioavailability of Curcumin Nanocrystals Prepared by Hot Melt Extrusion Technology.International journal of nanomedicine · 2024Article
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.Pharmaceutics · 2023Review
- Glycol chitosan stabilized nanomedicine of lapatinib and doxorubicin for the management of metastatic breast tumor.Drug delivery and translational research · 2023Article
- Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.Materials (Basel, Switzerland) · 2023Article
- Sequential Flash NanoPrecipitation for the scalable formulation of stable core-shell nanoparticles with core loadings up to 90.International journal of pharmaceutics · 2023Article
- Continuous Spatiotemporal Therapy of A Full-API Nanodrug via Multi-Step Tandem Endogenous Biosynthesis.Nature communications · 2023Article
- Next-Generation Hydrogels as Biomaterials for Biomedical Applications: Exploring the Role of Curcumin.ACS omega · 2023Review
- Preparation and Evaluation of Curcumin Derivatives Nanoemulsion Based on Turmeric Extract and Its Antidepressant Effect.International journal of nanomedicine · 2023Article
- Silica-Based Nanomaterials for Diabetes Mellitus Treatment.Bioengineering (Basel, Switzerland) · 2022Review
- Smart drug delivery systems for precise cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Restorative biodegradable two-layered hybrid microneedles for melanoma photothermal/chemo co-therapy and wound healing.Journal of nanobiotechnology · 2022Article
- Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: From intrinsic physicochemical properties to external modification.Bioactive materials · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The use of different nanocarriers for delivering hydrophobic pharmaceutical agents to tumor sites has garnered major attention. Despite the merits of these nanocarriers, further studies are needed to improve their drug loading capacities (which are typically <10%) and reduce their potential systemic toxicity. Therefore, the development of alternative self-carried nanodrug delivery strategies without using inert carriers is highly desirable. In this study, we developed a self-carried curcumin (Cur) nanodrug for highly effective cancer therapy in vitro and in vivo with real-time monitoring of drug release. With a biocompatible C18PMH-PEG functionalization, the Cur nanoparticles (NPs) showed excellent dispersibility and outstanding stability in physiological environments with drug loading capacities >78 wt%. Both confocal microscopy and flow cytometry confirmed the cellular fluorescence "OFF-ON" activation and real-time monitoring of the Cur molecule release. In vitro and in vivo experiments clearly show that the therapeutic efficacy of the PEGylated Cur NPs is considerably better than that of free Cur. This self-carried strategy with real-time monitoring of drug release may open a new way for simultaneous cancer therapy and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.